Carregant...
A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Neprilysin Inhibition
Objective: To evaluate the efficacy, safety, and clinical significance of sacubitril/valsartan (Entresto) in patients with heart failure with a reduced ejection fraction (HFrEF). Data Sources: An extensive search was conducted on Ovid MEDLINE using keywords and medical subject headings LCZ696, sacub...
Guardat en:
| Publicat a: | J Pharm Technol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5998462/ https://ncbi.nlm.nih.gov/pubmed/34860952 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/8755122515622224 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|